|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
06-18-2010, 05:14 PM
|
|||
|
|||
Tasigna Approval Widened to Include Early Stages of Rare Leukemia
FRIDAY, June 18 (HealthDay News) -- The anti-cancer drug Tasigna (nilotinib) has received new approval from the U.S. Food and Drug Administration to include people in the early stages of a rare blood cancer called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+CP-CML), the agency said in a news release.
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Tasigna receives approval for chronic myeloid leukemia in Canada | cancerfr | Leukemia | 0 | 08-21-2010 02:37 AM |
| FDA Approves Tasigna For Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demo | cancerfr | Leukemia | 0 | 06-24-2010 12:35 AM |
| FDA Approves Tasigna for Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demo | cancerfr | Leukemia | 0 | 06-18-2010 03:06 PM |
| FDA approves new indication for Tasigna in treatment of rare blood cancer | cancerfr | Oral Cancer | 0 | 06-18-2010 03:06 PM |
| FDA Approves Novartis' Tasigna For Adults In Earlier Cancer Stages | cancerfr | Bone Cancer | 0 | 06-18-2010 03:06 PM |
Linear Mode
